Regenerative medicine – time to cut through the hype
This article was originally published in Clinica
Regenerative medicine is widely seen as playing a vital future role in difficult-to-treat conditions like diabetes, Parkinson's disease and stroke. But can it really deliver on its promise, or is it simply being hyped up to persuade investors to put money into what is a young and unpredictable area of research?
You may also be interested in...
As fears grow that a full-blown COVID-19 pandemic may be on the way, a European public-private consortium is to make available a total of €45m (US$49m) in funding for projects aimed at accelerating the development of diagnostics and therapeutics to help tackle the current outbreak and any future coronavirus threats.
Europe’s Innovative Medicines Initiative is calling for R&D projects aimed at tackling the spread of COVID-19, saying that collaborative ventures have the potential to accelerate the development of therapeutics and diagnostics to tackle this and future coronavirus outbreaks.
Europe’s Innovative Medicines Initiative is to get €90m in funding for programs targeting the coronavirus outbreak.